共 9 条
[1]
Tefferi A(2012)One thousand patients with primary myelofibrosis: the mayo clinic experience Mayo Clin. Proc. 87 25-33
[2]
Barraco D(2016)Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations Blood Cancer J. 6 1187-1192
[3]
Shirai CL(2017)Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome Nat. Commun. 8 896-902
[4]
Tefferi A(2017)Risk factors and a prognostic model for post-splenectomy survival in myelofibrosis Am. J. Hematol. 92 66-68
[5]
Tefferi A(2017)A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence Leukemia 31 908-919
[6]
Begna KH(2012)Long-term outcome of pomalidomide therapy in myelofibrosis Am. J. Hematol. 87 1322-1327
[7]
Tefferi A(2015)A pilot study of the telomerase inhibitor imetelstat for myelofibrosis N. Engl. J. Med. 373 1823-1830
[8]
Pardanani A(2013)Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis Leukemia 27 undefined-undefined
[9]
Asshoff M(2017)Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents Blood 129 undefined-undefined